GS Conference Call (in 30 mins): Takeaways from Annual Macula Society Meeting
The analyst was asking about protocol T and then the Novartis drug rth258
Towards the end the Dr. Nguyen mentioned that the Squalamine data was very interesting. I have sent you the coordinates of the call. If you would like to discuss Squalamine with Ohr Pharmaceutical or myself, please do not hesitate to call.
The balance of the phase 2 data will be out by the end of March.
: Lau, Irene [mailto:Irene.Z.Lau@gs.com] On Behalf Of Flynn, Terence
Sent: Friday, February 27, 2015 12:02 PM
Subject: GS Conference Call (in 30 mins): Takeaways from Annual Macula Society Meeting - TODAY 12:30pm ET
Goldman Sachs Global Investment Research
Goldman Sachs Conference Call
Takeaways from Annual Macula Society Meeting
Quan Dong Nguyen, MD, Msc, Professor and Chair of Ophthalmology at University of Nebraska
Hosted by:
Terence Flynn
GS Biotechnology Analyst
Friday, February 27, 2015
12:30PM ET
Dial-in information:
US (Toll-Free): 1-877-208-2954
International: 1-973-528-0056
Conference Entry Code: 704999
Replay information:
US (Toll-Free): 1-800-332-6854
International: 1- 973-528-0005
Code: 704999
**Replay will be available for two weeks**
Discussion will include Protocol-T Phase 3 data evaluating Eylea vs. Lucentis vs. Avastin in DME, and NVS’ RTH-258 Ph2 wet AMD data
Potential names to be discussed include REGN, NVS, ROG.VX.
